Farxiga for diabetes
Pro Research Analysisby 
Searched over 200M research papers
Farxiga (Dapagliflozin) for Diabetes Management
Introduction to Farxiga (Dapagliflozin)
Farxiga, also known as dapagliflozin, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the treatment of type 2 diabetes mellitus (T2DM). It works by inhibiting the SGLT2 protein in the renal proximal tubule, which reduces renal glucose reabsorption and increases urinary glucose excretion, thereby lowering blood glucose levels Maranghi2015Plosker2014Vivian2015.
Pharmacokinetics and Pharmacodynamics
Dapagliflozin exhibits favorable pharmacokinetic (PK) and pharmacodynamic (PD) properties. It is highly selective and reversible, making it effective in reducing glycemic levels without significant drug-drug interactions Maranghi2015Dhillon2019. The drug's mechanism of action is independent of insulin secretion or action, which allows it to be used in combination with other antihyperglycemic agents Plosker2014Vivian2015.
Clinical Efficacy
Glycemic Control
Clinical trials have consistently demonstrated that dapagliflozin effectively reduces glycosylated hemoglobin (HbA1c), fasting plasma glucose levels, and body weight when used as monotherapy or in combination with other glucose-lowering agents Plosker2014Davis2016Vivian2015. The effects are maintained over long-term follow-up periods of up to four years .
Cardiovascular and Renal Benefits
Dapagliflozin has shown potential cardiovascular benefits, including a reduction in the rate of cardiovascular death or hospitalization for heart failure (HHF) and possibly slowing the progression of renal disease in patients with established atherosclerotic cardiovascular disease (CVD) or multiple risk factors for CVD . However, its effects on diabetic complications and long-term cardiovascular outcomes are still under investigation Plosker2014Dhillon2019.
Safety and Tolerability
Common Adverse Effects
Dapagliflozin is generally well tolerated, with a low risk of hypoglycemia. However, it is associated with an increased risk of genital mycotic infections, particularly in women, and urinary tract infections Plosker2014Vivian2015Aschenbrenner2011. Other common adverse effects include nasopharyngitis and hypotension, especially in patients with pre-existing renal impairment .
Serious Concerns
There are concerns about the potential risk of bladder cancer and diabetic ketoacidosis (DKA) with dapagliflozin use. Although the incidence of these conditions is rare, ongoing research is needed to further assess these risks Maranghi2015Vivian2015P2023. The FDA has also issued warnings about the risk of acute kidney injury associated with dapagliflozin, recommending careful monitoring of kidney function during treatment .
Conclusion
Dapagliflozin (Farxiga) offers a novel and effective treatment option for type 2 diabetes, providing significant glycemic control and potential cardiovascular and renal benefits. While it is generally well tolerated, healthcare providers should be aware of the associated risks and monitor patients accordingly. Given its unique mechanism of action and favorable efficacy profile, dapagliflozin remains a valuable addition to the diabetes management arsenal.
Sources and full results
Most relevant research papers on this topic
Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes
Dapagliflozin effectively reduces glycemic levels in type 2 diabetes patients, but increased risk of infections and volume depletion are concerns.
Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Dapagliflozin, an SGLT2 inhibitor, improves glycemic control in adults with type 2 diabetes by inhibiting renal reabsorption of glucose, offering a novel treatment option independent of insulin secretion or action.
DOI
Dapagliflozin (Farxiga) for Type 2 Diabetes Mellitus.
Dapagliflozin effectively lowers A1C levels in Type 2 diabetes patients, but its effect on diabetes-associated morbidity and mortality remains unstudied.
Guideline Summary NGC (2016): Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Canagliflozin and dapagliflozin are effective type 2 diabetes medicines, but the FDA has strengthened its warning about acute kidney injury risks.
DOI